Clinical study of Atorvastatin combined with enteral nutrition in the treatment of senile non-alcoholic fatty liver with metabolic syndrome
MIAO Yanxia1 WANG Fang2 QIAO Liangmei1 LIU Yixin1 LYV Yangmei1
1.Department of Nutrition, Xi′an Central Hospital Affiliated to Xi′an Jiaotong University, Shaanxi Province, Xi′an 710003, China;
2.Department of Endocrinology, Xi′an Central Hospital Affiliated to Xi′an Jiaotong University, Shaanxi Province, Xi′an 710003, China
Abstract：Objective To investigate the clinical effect of Atorvastatin combined with enteral nutrition in the treatment of senile non-alcoholic fatty liver with metabolic syndrome. Methods From January 2017 to May 2018, 83 elderly patients with non-alcoholic fatty liver disease associated with metabolic syndrome admitted to Xi′an Central Hospital Affiliated to Xi′an Jiaotong University were selected as research objects. Patients were randomly divided into the control group (n = 41) and the study group (n = 42) according to the random number table method. The control group was treated with enteral nutrition, and the study group was treated with Atorvastatin on this basis. The clinical efficacy of the two groups after treatment, the nutritional indexes before and after treatment, and the levels of inflammatory factors including interleukin-6 (IL-6), tumor necrosis factor alpha (TNF-α), and high-sensitivity C-reactive protein (hs-CRP) were compared between the two groups. Results The total clinical effective rate of the study group was significantly higher than that of the control group (P ＜ 0.05). IL-6, TNF-α and hs-CRP of the two groups before treatment showed no significant difference (P ＞ 0.05), while IL-6, TNF-α and hs-CRP of the two groups after treatment were lower than before treatment, and the study group were significantly lower than the control group (P ＜ 0.05). Body mass index (BMI), triceps brachii musculocutaneous fold thickness (TSF) and waist-to-hip ratio (WHR) of the two groups before treatment showed no statistically significant difference (P ＞ 0.05). After treatment, BMI and TSF of the two groups both decreased, and BMI of the study group was lower than that of the control group (P ＜ 0.05). TSF and WHR were compared between the two groups after treatment, and the difference was not statistically significant (P ＞ 0.05). The incidence of adverse reactions in the study group was significantly lower than that in the control group (P ＜ 0.05). Conclusion Atorvastatin combined with enteral nutrition in the treatment of senile non-alcoholic fatty liver with metabolic syndrome has definite effect, can significantly improve the nutritional status of patients, reduce the inflammatory response of patients, and has certain clinical application value.
缪艳霞1 王芳2 乔良美1 刘怡欣1 吕阳梅1. 阿托伐他汀联合肠内营养治疗老年非酒精性脂肪肝伴代谢综合征的临床研究[J]. 中国医药导报, 2019, 16(10): 80-83.
MIAO Yanxia1 WANG Fang2 QIAO Liangmei1 LIU Yixin1 LYV Yangmei1. Clinical study of Atorvastatin combined with enteral nutrition in the treatment of senile non-alcoholic fatty liver with metabolic syndrome. 中国医药导报, 2019, 16(10): 80-83.
2019, Vol. 16 
京公网安备 11010502046598号